Statin + fenofibrate

1 paper3 findings

PubChem 54454 PubChem 3339 ChEBI 9150 ChEBI 5001

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Humans1

Outcomes

Coded safety events

no changein humans1

1 study

Statin + fenofibrate has no effect on coded safety events in humans.
“and coded safety events were not significantly different between groups.”
HumansNon-dialysis-dependent CKD, hypertriglyceridemia, and ischemic heart disease; compared with statin monotherapy
Combined statin and fenofibrate therapy and cardiorenal outcomes in patients with CKD, dyslipidemia, and ischemic heart disease
Clinical kidney journal1 Oct 2026

Associations

End-stage kidney disease necessitating dialysis

downin humans1HR 0.79

1 study

Statin + fenofibrate is associated with end-stage kidney disease necessitating dialysis in humans (HR 0.79, 95% CI 0.67–0.92).
“and ESKD necessitating dialysis (264 [8.3%] vs 335 [10.5%]; HR, 0.79; 95% CI, 0.67-0.92).”
HumansNon-dialysis-dependent CKD, hypertriglyceridemia, and ischemic heart disease; compared with statin monotherapymedian 881 days with combination therapy and 925 days with statin monotherapy
Combined statin and fenofibrate therapy and cardiorenal outcomes in patients with CKD, dyslipidemia, and ischemic heart disease
Clinical kidney journal1 Oct 2026

More on End-stage kidney disease necessitating dialysis

Expanded major adverse cardiovascular events

downin humans1HR 0.93

1 study

Statin + fenofibrate is associated with expanded major adverse cardiovascular events in humans (HR 0.93, 95% CI 0.86–0.99).
“Combination therapy was associated with lower risks of MACE [1472 [46.1%] vs 1576 [49.4%] events; HR, 0.93; 95% confidence interval (CI), 0.86-0.99]”
HumansNon-dialysis-dependent CKD, hypertriglyceridemia, and ischemic heart disease; compared with statin monotherapymedian 881 days with combination therapy and 925 days with statin monotherapy
Combined statin and fenofibrate therapy and cardiorenal outcomes in patients with CKD, dyslipidemia, and ischemic heart disease
Clinical kidney journal1 Oct 2026